MPE has received funding from the following sources in 2024 and 2025:
Industry supporters
- AbbVie
- Alexion
- Amgen
- AstraZeneca
- BeiGene
- Binding Site
- Bristol Myers Squibb
- GlaxoSmithKline
- Johnson & Johnson
- Kite, A Gilead Company
- Menarini Stemline
- Oncopeptides
- Pfizer
- Prothena
- Regeneron
- Roche
- Sanofi
- Takeda
Public supporters
Horizon Europe
Innovative Medicine Initiative (IMI)
- Horizon Europe ASCERTAIN
- Horizon Europe CERTAINTY
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101094938.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. Grant agreement 101136379.
- SISAQOL IMI
You can freely download the funding sources reports by clicking on the links below:
